type 2 diabetes
Conditions
Interventions
perioperative periods, liraglutide 0.9mg
insulin therapy
Sponsors
Takatsuki redcross hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults (age 20 and above) with type 2 diabetes25 who received at least 3 months of previous antidiabetic treatment, had values of BMI over 20 kg/m2 inclusive with HbA1c 6.0% and above who were scheduled to undergo elective surgery within ERAS protocols were eligible
Exclusion criteria
Exclusion criteria: Patients who were to undergo gastrointestinal or neurosurgical procedures were excluded. Patients who tested positive for anti-GAD (glutamate decarboxylase) antibodies or with elevated ALT (2 times upper normal range) were excluded from the study. Patients with autonomic neuropathy or recurrent severe hypoglycemia were also excluded. Patients who had been administered any drug except for oral antidiabetic drugs (OADs), which could interfere with glucose level or bodyweight (i.e. systemic corticosteroids, orlistat or sibutramine), were also excluded. Patients who had been administered sGLT-2 inhibitor or thiazolidinediones were excluded because these medicines could interfere with accurate bodyweight changes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood glucose fluctuation | — |
Secondary
| Measure | Time frame |
|---|---|
| insulin dosage and days prescribed for the correction of elevated blood glucose levels, frequency of hypoglycemic events, tolerance,changes in lean body mass, changes in body fat and visceral fat area | — |
Countries
Japan
Contacts
Public ContactKaneko Shizuka
Takatsuki Redcross Hospital Diabetes, endocrinology and life-related disease
Outcome results
None listed